A comparative study of blood cell count in four automated hematology analyzers: An evaluation of the impact of preanalytical factors

Autor: Annika Åstrand, Cecilia Wingren, Claire Walton, Johan Mattsson, Komal Agrawal, Madelene Lindqvist, Lina Odqvist, Björn Burmeister, Steven Eck, Glen Hughes, Gabriela Luporini Saraiva, Anna Schantz, Ioannis Psallidas, Christopher McCrae

Publikováno v: PLoS ONE, Vol 19, Iss 5 (2024)

Externí odkaz: https://doaj.org/article/f5cad6e900424cb396d36459f878b7bc

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

Autor: Julio Rosenstock, Chantal Mathieu, Hungta Chen, Ricardo Garcia-Sanchez, Gabriela Luporini Saraiva

Publikováno v: Archives of Endocrinology and Metabolism, Vol 62, Iss 4, Pp 424-430

ABSTRACT Objective: This analysis compared the efficacy and safety of the sodium-glucose cotransporter-2 (SGLT2) inhibitor, dapagliflozin, and the dipeptidyl peptidase-4 (DPP4) inhibitor, saxagliptin, both added on to metformin. Materials and methods

Externí odkaz: https://doaj.org/article/40485079a3b145e193ff5dbb10aef118

Type 2 diabetes and heart failure: insights from the global DISCOVER study

Autor: Suzanne V. Arnold, Kamlesh Khunti, Fabrice Bonnet, Bernard Charbonnel, Hungta Chen, Javier Cid‐Ruzafa, Andrew Cooper, Peter Fenici, Marilia B. Gomes, Niklas Hammar, Linong Ji, Gabriela Luporini‐Saraiva, Jesús Medina, Antonio Nicolucci, Larisa Ramirez, Marina V. Shestakova, Iichiro Shimomura, Filip Surmont, Fengming Tang, Jiten Vora, Hirotaka Watada, Mikhail Kosiborod, the DISCOVER investigators

Publikováno v: ESC Heart Failure, Vol 8, Iss 2, Pp 1711-1716 (2021)
ESC Heart Failure

Aims Heart failure (HF) is increasingly recognized as a major cause of morbidity and mortality in patients with type 2 diabetes (T2D), but the global epidemiology and treatment of HF in T2D are not well defined. This study aimed to examine the global

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92976320ad5dd438bc38fa7dc2234fdf
https://doaj.org/article/6f0d5cf6e07a4fcc98c4a0e71fee4e3d

Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study

Autor: Niklas Hammar, Filip Surmont, Gabriela Luporini Saraiva, Hungta Chen, Andrew Cooper, Hirotaka Watada, Marina Vladimirovna Shestakova, Wolfgang Rathmann, Paul Leigh, Fabrice Bonnet, Larisa Ramirez, Discover investigators, Fengming Tang, Antonio Nicolucci, Linong Ji, Jesús Medina

Publikováno v: Diabetes Research and Clinical Practice
Diabetes Research and Clinical Practice, Elsevier, 2021, 178, pp.108947. ⟨10.1016/j.diabres.2021.108947⟩
Diabetes Research and Clinical Practice, 2021, 178, pp.108947. ⟨10.1016/j.diabres.2021.108947⟩

International audience; Aims: To assess the effects of glycated haemoglobin (HbA(1c)) levels at time of glucose-lowering treatment intensification in DISCOVER, a global observational study of patients with type 2 diabetes (T2D) initiating second-line

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c88d1b407e4b48e6f0f24bfb0890ee2
https://hal.archives-ouvertes.fr/hal-03476924

1279-P: Socioeconomic Factors Associated with Poor Glycemic Control in People with Type 2 Diabetes: The DISCOVER Study

Autor: Marilia B. Gomes, Shaukat M. Sadikot, Iichiro Shimomura, Hungta Chen, Antonio Nicolucci, Stuart Pocock, Gabriela Luporini Saraiva, Jesus Medina, Peter Fenici, Fengming Tang, Wolfgang Rathmann, Marina V. Shestakova, Javier Cid-Ruzafa, Kamlesh Khunti, Filip Surmont, Hirotaka Watada

Publikováno v: Diabetes. 68

Background: DISCOVER is a 3-year, observational study of patients with type 2 diabetes (T2D) initiating second-line glucose-lowering therapy in 38 countries. We assessed socioeconomic factors associated with poor glycemic control (HbA1c ≥ 9.0%) at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ec45c21464466731bc799dc14f9b908
https://doi.org/10.2337/db19-1279-p